Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology

ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial lung disease of unknown cause, which predominantly affects elderly men who are current or former smokers. Even though it is an uncommon disease, it is of great importance because of its severity and poor prognosis. In recent decades, several pharmacological treatment modalities have been investigated for the treatment of this disease, and the classic concepts have therefore been revised. The purpose of these guidelines was to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of IPF in Brazil. We sought to provide guidance on the practical issues faced by clinicians in their daily lives. Patients of interest, Intervention to be studied, Comparison of intervention and Outcome of interest (PICO)-style questions were formulated to address aspects related to the use of corticosteroids, N-acetylcysteine, gastroesophageal reflux medications, endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, pirfenidone, and nintedanib. To formulate the PICO questions, a group of Brazilian specialists working in the area was assembled and an extensive review of the literature on the subject was carried out. Previously published systematic reviews with meta-analyses were analyzed for the strength of the compiled evidence, and, on that basis, recommendations were developed by employing the Grading of Recommendations Assessment, Development and Evaluation approach. The authors believe that the present document represents an important advance to be incorporated in the approach to patients with IPF, aiming mainly to improve its management, and can become an auxiliary tool for defining public policies related to IPF.

Saved in:
Bibliographic Details
Main Authors: Baddini-Martinez,José, Ferreira,Juliana, Tanni,Suzana, Alves,Luis Renato, Cabral Junior,Benedito Francisco, Carvalho,Carlos Roberto Ribeiro, Cezare,Talita Jacon, Costa,Claudia Henrique da, Gazzana,Marcelo Basso, Jezler,Sérgio, Kairalla,Ronaldo Adib, Kawano-Dourado,Leticia, Lima,Mariana Silva, Mancuzo,Eliane, Moreira,Maria Auxiliadora Carmo, Rodrigues,Marcelo Palmeira, Rodrigues,Silvia Carla Sousa, Rubin,Adalberto Sperb, Rufino,Rogério Lopes, Steidle,Leila John Marques, Storrer,Karin, Baldi,Bruno Guedes
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Pneumologia e Tisiologia 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132020000200400
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1806-37132020000200400
record_format ojs
spelling oai:scielo:S1806-371320200002004002020-02-28Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodologyBaddini-Martinez,JoséFerreira,JulianaTanni,SuzanaAlves,Luis RenatoCabral Junior,Benedito FranciscoCarvalho,Carlos Roberto RibeiroCezare,Talita JaconCosta,Claudia Henrique daGazzana,Marcelo BassoJezler,SérgioKairalla,Ronaldo AdibKawano-Dourado,LeticiaLima,Mariana SilvaMancuzo,ElianeMoreira,Maria Auxiliadora CarmoRodrigues,Marcelo PalmeiraRodrigues,Silvia Carla SousaRubin,Adalberto SperbRufino,Rogério LopesSteidle,Leila John MarquesStorrer,KarinBaldi,Bruno Guedes Idiopathic pulmonary fibrosis GRADE approach Pulmonary fibrosis/drug therapy Practice guideline ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial lung disease of unknown cause, which predominantly affects elderly men who are current or former smokers. Even though it is an uncommon disease, it is of great importance because of its severity and poor prognosis. In recent decades, several pharmacological treatment modalities have been investigated for the treatment of this disease, and the classic concepts have therefore been revised. The purpose of these guidelines was to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of IPF in Brazil. We sought to provide guidance on the practical issues faced by clinicians in their daily lives. Patients of interest, Intervention to be studied, Comparison of intervention and Outcome of interest (PICO)-style questions were formulated to address aspects related to the use of corticosteroids, N-acetylcysteine, gastroesophageal reflux medications, endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, pirfenidone, and nintedanib. To formulate the PICO questions, a group of Brazilian specialists working in the area was assembled and an extensive review of the literature on the subject was carried out. Previously published systematic reviews with meta-analyses were analyzed for the strength of the compiled evidence, and, on that basis, recommendations were developed by employing the Grading of Recommendations Assessment, Development and Evaluation approach. The authors believe that the present document represents an important advance to be incorporated in the approach to patients with IPF, aiming mainly to improve its management, and can become an auxiliary tool for defining public policies related to IPF.info:eu-repo/semantics/openAccessSociedade Brasileira de Pneumologia e TisiologiaJornal Brasileiro de Pneumologia v.46 n.2 20202020-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132020000200400en10.36416/1806-3756/e20190423
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Baddini-Martinez,José
Ferreira,Juliana
Tanni,Suzana
Alves,Luis Renato
Cabral Junior,Benedito Francisco
Carvalho,Carlos Roberto Ribeiro
Cezare,Talita Jacon
Costa,Claudia Henrique da
Gazzana,Marcelo Basso
Jezler,Sérgio
Kairalla,Ronaldo Adib
Kawano-Dourado,Leticia
Lima,Mariana Silva
Mancuzo,Eliane
Moreira,Maria Auxiliadora Carmo
Rodrigues,Marcelo Palmeira
Rodrigues,Silvia Carla Sousa
Rubin,Adalberto Sperb
Rufino,Rogério Lopes
Steidle,Leila John Marques
Storrer,Karin
Baldi,Bruno Guedes
spellingShingle Baddini-Martinez,José
Ferreira,Juliana
Tanni,Suzana
Alves,Luis Renato
Cabral Junior,Benedito Francisco
Carvalho,Carlos Roberto Ribeiro
Cezare,Talita Jacon
Costa,Claudia Henrique da
Gazzana,Marcelo Basso
Jezler,Sérgio
Kairalla,Ronaldo Adib
Kawano-Dourado,Leticia
Lima,Mariana Silva
Mancuzo,Eliane
Moreira,Maria Auxiliadora Carmo
Rodrigues,Marcelo Palmeira
Rodrigues,Silvia Carla Sousa
Rubin,Adalberto Sperb
Rufino,Rogério Lopes
Steidle,Leila John Marques
Storrer,Karin
Baldi,Bruno Guedes
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology
author_facet Baddini-Martinez,José
Ferreira,Juliana
Tanni,Suzana
Alves,Luis Renato
Cabral Junior,Benedito Francisco
Carvalho,Carlos Roberto Ribeiro
Cezare,Talita Jacon
Costa,Claudia Henrique da
Gazzana,Marcelo Basso
Jezler,Sérgio
Kairalla,Ronaldo Adib
Kawano-Dourado,Leticia
Lima,Mariana Silva
Mancuzo,Eliane
Moreira,Maria Auxiliadora Carmo
Rodrigues,Marcelo Palmeira
Rodrigues,Silvia Carla Sousa
Rubin,Adalberto Sperb
Rufino,Rogério Lopes
Steidle,Leila John Marques
Storrer,Karin
Baldi,Bruno Guedes
author_sort Baddini-Martinez,José
title Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology
title_short Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology
title_full Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology
title_fullStr Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology
title_full_unstemmed Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology
title_sort brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. official document of the brazilian thoracic association based on the grade methodology
description ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial lung disease of unknown cause, which predominantly affects elderly men who are current or former smokers. Even though it is an uncommon disease, it is of great importance because of its severity and poor prognosis. In recent decades, several pharmacological treatment modalities have been investigated for the treatment of this disease, and the classic concepts have therefore been revised. The purpose of these guidelines was to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of IPF in Brazil. We sought to provide guidance on the practical issues faced by clinicians in their daily lives. Patients of interest, Intervention to be studied, Comparison of intervention and Outcome of interest (PICO)-style questions were formulated to address aspects related to the use of corticosteroids, N-acetylcysteine, gastroesophageal reflux medications, endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, pirfenidone, and nintedanib. To formulate the PICO questions, a group of Brazilian specialists working in the area was assembled and an extensive review of the literature on the subject was carried out. Previously published systematic reviews with meta-analyses were analyzed for the strength of the compiled evidence, and, on that basis, recommendations were developed by employing the Grading of Recommendations Assessment, Development and Evaluation approach. The authors believe that the present document represents an important advance to be incorporated in the approach to patients with IPF, aiming mainly to improve its management, and can become an auxiliary tool for defining public policies related to IPF.
publisher Sociedade Brasileira de Pneumologia e Tisiologia
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132020000200400
work_keys_str_mv AT baddinimartinezjose brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT ferreirajuliana brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT tannisuzana brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT alvesluisrenato brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT cabraljuniorbeneditofrancisco brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT carvalhocarlosrobertoribeiro brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT cezaretalitajacon brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT costaclaudiahenriqueda brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT gazzanamarcelobasso brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT jezlersergio brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT kairallaronaldoadib brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT kawanodouradoleticia brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT limamarianasilva brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT mancuzoeliane brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT moreiramariaauxiliadoracarmo brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT rodriguesmarcelopalmeira brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT rodriguessilviacarlasousa brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT rubinadalbertosperb brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT rufinorogeriolopes brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT steidleleilajohnmarques brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT storrerkarin brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
AT baldibrunoguedes brazilianguidelinesforthepharmacologicaltreatmentofidiopathicpulmonaryfibrosisofficialdocumentofthebrazilianthoracicassociationbasedonthegrademethodology
_version_ 1756431136285786112